Wnt3a Facilitates SARS-CoV-2 Pseudovirus Entry into Cells.

ACE2 SARS-CoV-2 Wnt3a canonical pathway host factor virus entry β-catenin

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Dec 2023
Historique:
received: 21 11 2023
revised: 20 12 2023
accepted: 21 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

How ACE2 functions as the major host receptor of SARS-CoV-2 despite having low expression in the lungs is still unknown. To facilitate the development of therapeutic strategies against coronaviruses, gaining a deeper comprehension of the molecular mechanism of SARS-CoV-2 infection is imperative. In our previous study, we identified several potential host factors of SARS-CoV-2 using an shRNA arrayed screen, one of which was Wnt3a. Here, we validated the significance of Wnt3a, a potent activator of the Wnt/β-catenin signaling pathway, for SARS-CoV-2 entry into cells by evaluating the effects of its knockdown and overexpression on SARS-CoV-2 pseudotyped virus entry. Further analysis revealed that SARS-CoV-2 pseudotyped virus infection activates the canonical Wnt/β-catenin signaling pathway, which we found could subsequently stimulate ACE2 transcription. Collectively, our study identified Wnt3a as an important host factor that facilitates ACE2-mediated virus infection. Insight into the virus entry mechanism is impactful as it will aid in developing novel therapeutic strategies against current and future coronavirus pandemics.

Identifiants

pubmed: 38203386
pii: ijms25010217
doi: 10.3390/ijms25010217
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Science and Technology Council, Taiwan
ID : MOST 111-2320-B-039-060
Organisme : National Science and Technology Council, Taiwan
ID : NSTC 112-2635-B-039-001
Organisme : China Medical University Hospital, Taiwan
ID : DMR-112-127
Organisme : China Medical University Hospital, Taiwan
ID : DMR-112-127

Auteurs

Ivonne Melano (I)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.

Hui-Jye Chen (HJ)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.

Loveness Ngwira (L)

International Master's Program of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.

Pang-Hung Hsu (PH)

Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung 202, Taiwan.
Center of Excellence for the Oceans, National Taiwan Ocean University, Keelung 202, Taiwan.
Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.

Li-Lan Kuo (LL)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.

Lloyd Noriega (L)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.

Wen-Chi Su (WC)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
International Master's Program of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan.
Drug Development Center, China Medical University, Taichung 404, Taiwan.

Classifications MeSH